Fesoterodine

Generic Name
Fesoterodine
Brand Names
Toviaz
Drug Type
Small Molecule
Chemical Formula
C26H37NO3
CAS Number
286930-02-7
Unique Ingredient Identifier
621G617227
Background

Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

Indication

适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。

Associated Conditions
Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
Associated Therapies
-
Clinical Trials
Related News

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Phase 1
Completed
Conditions
Treatment of Overactive Bladder
Interventions
Drug: Fesoterodine
First Posted Date
2009-05-15
Last Posted Date
2018-10-16
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT00902187
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Phase 1
Completed
Conditions
Treatment of Overactive Bladder
Interventions
Drug: Fesoterodine
First Posted Date
2009-05-15
Last Posted Date
2018-09-28
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT00902681
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

First Posted Date
2009-03-17
Last Posted Date
2011-11-24
Lead Sponsor
University of California, San Francisco
Target Recruit Count
645
Registration Number
NCT00862745
Locations
🇺🇸

Oregon Health and Science University, Portland, Oregon, United States

🇺🇸

University of Texas Health Science Center San Antonio, San Antonio, Texas, United States

🇺🇸

University of Virginia-Women's Midlife Health Center, Charlottesville, Virginia, United States

and more 10 locations

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

First Posted Date
2009-03-09
Last Posted Date
2011-11-24
Lead Sponsor
Pfizer
Target Recruit Count
21
Registration Number
NCT00857896
Locations
🇺🇸

Pfizer Investigational Site, Liberty Township, Ohio, United States

Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect

Phase 1
Completed
Conditions
Therapeutic Equivalency
Food
Interventions
Drug: Fesoterodine
First Posted Date
2008-12-11
Last Posted Date
2010-03-24
Lead Sponsor
Pfizer
Target Recruit Count
108
Registration Number
NCT00807118
Locations
🇯🇵

Pfizer Investigational Site, Shinjuku-ku, Tokyo, Japan

UK Study Assessing Flexible Dose Fesoterodine in Adults

Phase 4
Completed
Conditions
Urinary Bladder, Overactive
Interventions
Drug: Fesoterodine
First Posted Date
2008-12-10
Last Posted Date
2011-01-26
Lead Sponsor
Pfizer
Target Recruit Count
331
Registration Number
NCT00806494
Locations
🇬🇧

Pfizer Investigational Site, Swindon, United Kingdom

Phase1, Single Dose, Crossover Study to Determine Bioequivalence

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Fesoterodine
First Posted Date
2008-11-06
Last Posted Date
2010-09-09
Lead Sponsor
Pfizer
Target Recruit Count
37
Registration Number
NCT00786240
Locations
🇸🇬

Pfizer Investigational Site, Singapore, Singapore

Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy

First Posted Date
2008-06-05
Last Posted Date
2018-11-02
Lead Sponsor
Pfizer
Target Recruit Count
823
Registration Number
NCT00691093
Locations
🇸🇰

Pfizer Investigational Site, Zvolen, Slovakia

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

First Posted Date
2008-02-08
Last Posted Date
2011-02-02
Lead Sponsor
Pfizer
Target Recruit Count
2417
Registration Number
NCT00611026
Locations
🇺🇦

Pfizer Investigational Site, Zaporizhzhia, Ukraine

Fesoterodine "add-on" Male Overactive Bladder Study

Phase 3
Completed
Conditions
Overactive Bladder Syndrome
Interventions
Drug: Placebo
Drug: Fesoterodine
First Posted Date
2007-10-19
Last Posted Date
2011-02-18
Lead Sponsor
Pfizer
Target Recruit Count
947
Registration Number
NCT00546637
Locations
🇹🇭

Pfizer Investigational Site, Amphoe Mueang, Chiang Mai, Thailand

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy